Thermo Fisher Scientific introduces new Mass Spec and Chromatography technologies

USA – Thermo Fisher Scientific has introduced new mass spectrometry (MS) instruments, workflows, and software, which it displayed at the 69th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in Philadelphia, Pennsylvania.

Thermo Scientific’s Orbitrap Exploris MX mass detector enables biopharmaceutical laboratories to use the multi-attribute method (MAM) and perform intact analysis of monoclonal antibodies, as well as oligonucleotide mass determination and peptide mapping.

The new system streamlines the transition of biotherapeutics from development to manufacturing and allows quality control (QC) customers to use the same method established earlier in a molecule’s journey to commercialization, which speeds up the biopharma pipeline, according to a press release issued on November 1, 2021.

Reduced downtime, maintenance, and seamless method transfers can also benefit labs, increasing efficiency.

The new MS system also provides improved data quality, allowing users with limited mass spectrometric experience to obtain high-confidence results.

Thermo Scientific’s MAM 2.0 workflow is intended to simplify biopharmaceutical characterization, process monitoring, and release testing by replacing multiple traditional assays with a single comprehensive analysis that provides insights on multiple critical product quality attributes.

MAM 2.0 includes the training, ongoing support, and collaboration required to improve laboratory analytical workflows in R&D, manufacturing, and QC environments.

The new workflow allows for the use of the same platform throughout a process, allowing for the seamless transfer of data and knowledge across teams and departments.

According to Thermo Fisher, this capability eliminates bottlenecks commonly encountered by organizations transitioning therapeutics from development to manufacturing.

The company’s offering for proteomic researchers is a combination of Thermo Scientific Proteome Discoverer 3.0 software and CHIMERYS, a cloud-native search algorithm for peptide identification by MSAID, a privately held informatics spin-off company from the chair of Proteomics and Bioanalytics at the Technical University of Munich, Germany.

This offering will improve researchers’ ability to identify peptides and proteins, allowing for a more comprehensive and in-depth understanding of biological systems.

The new system uses artificial intelligence to reimagine tandem mass spectral analysis, increasing peptide coverage and quantitation capabilities.

Thermo Scientific Compound Discoverer 3.3 software includes an improved peak detection algorithm and peak quality rating, allowing scientists performing small-molecule analysis in metabolomics, environmental, food safety, clinical, and forensics laboratories to detect compounds much faster and more sensitively.

Thermo Scientific BioPharma Finder 5.0 software boosts analytical throughput and confidence by providing built-for-purpose data processing, curation, and customizable reporting, all of which are expected to add new capabilities to biotherapeutic workflows.

Lastly, Thermo Scientific LipidSearch 5.0 software now supports direct infusion workflows. The software includes a 1.5 million lipid database, allowing for real-time monitoring as well as more accurate lipid quantitation.

Commenting on the new developments, Dan Shine, senior vice-president and president, Analytical Instruments, Thermo Fisher Scientific said: “We’re honored to have played an essential role in this effort. The new instruments, software, and workflows that we’re unveiling today will further support innovation across proteomics, biopharmaceutical characterization, and data acquisition while also ensuring that scientists can continue their critical ongoing research.”

Would you like to get regular updates of such news articles? Subscribe to our HealthCare Africa News, email newsletters, which provide the latest news insights from Africa and the World’s health, pharma and biotech industry. SUBSCRIBE HERE

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.